These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1700 related articles for article (PubMed ID: 15765026)

  • 21. Prognostic value of thyroglobulin after thyroidectomy before ablative radioiodine therapy in thyroid cancer.
    Grünwald F; Menzel C; Fimmers R; Zamora PO; Biersack HJ
    J Nucl Med; 1996 Dec; 37(12):1962-4. PubMed ID: 8970514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
    Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
    Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Differentiated thyroid carcinoma, 1972-1992. Follow-up, detection of recurrences and prognostic factors].
    Obiols G; Simó R; Burgos R; Tresserras R; Galofré P; Masmiquel L; Hernández C; Mesa J
    Med Clin (Barc); 1997 Nov; 109(19):738-43. PubMed ID: 9470182
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients.
    Pötzi C; Moameni A; Karanikas G; Preitfellner J; Becherer A; Pirich C; Dudczak R
    Clin Endocrinol (Oxf); 2006 Oct; 65(4):519-23. PubMed ID: 16984246
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
    Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
    Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overview on the use of recombinant human thyrotropin in thyroid cancer of follicular cell origin.
    Zanotti-Fregonara P; Toubert ME; Taieb D; Ravasi L; Rubello D; Hindie E
    Minerva Endocrinol; 2008 Jun; 33(2):53-65. PubMed ID: 18332849
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recombinant human TSH in radioiodine treatment of differentiated thyroid cancer.
    Kovatcheva RD; Hadjieva TD; Kirilov GG; Lozanov BS
    Nucl Med Rev Cent East Eur; 2004; 7(1):13-9. PubMed ID: 15318305
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blood thyroglobulin and TSH receptor mRNA detection by RT-PCR in the follow-up of differentiated thyroid cancer patients.
    Torosian L; Manrique G; Alvarez B; Lago G; Roca R; Belzarena C
    Rev Esp Med Nucl; 2010; 29(3):109-13. PubMed ID: 20399540
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
    Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does a highly sensitive thyroglobulin (Tg) assay change the clinical management of low-risk patients with thyroid cancer with Tg on T4 < 1 ng/ml determined by traditional assays?
    Rosario PW; Purisch S
    Clin Endocrinol (Oxf); 2008 Mar; 68(3):338-42. PubMed ID: 17850379
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
    Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
    J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of recombinant thyroid-stimulating hormone (rhTSH) in the detection and management of well-differentiated thyroid carcinoma: a roundtable discussion.
    Schlumberger MJ; Incerti C; Pacini F; Reiners C
    J Endocrinol Invest; 1999; 22(11 Suppl):35-41. PubMed ID: 10727004
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence, clinical significance and prognostic value of anti-thyroglobulin antibodies in the follow-up of patients with differentiated thyroid carcinoma: a retrospective study.
    Pedrazzini L; Baroli A; Lomuscio G; Marzoli L
    Minerva Endocrinol; 2009 Sep; 34(3):195-203. PubMed ID: 19859043
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differentiated thyroid carcinoma in children and adolescents: a 37-year experience in 85 patients.
    Dottorini ME; Vignati A; Mazzucchelli L; Lomuscio G; Colombo L
    J Nucl Med; 1997 May; 38(5):669-75. PubMed ID: 9170425
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Differentiated thyroid carcinoma--how to improve the long-term results? Twenty-five-year outcomes of 850 patients].
    Melliere D; Hindie E; Becquemin JP; Desgranges P; Allaire E; Geachan E
    Bull Acad Natl Med; 2006 Jan; 190(1):89-106; discussion 106-9. PubMed ID: 16878448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer.
    Iervasi A; Iervasi G; Ferdeghini M; Solimeo C; Bottoni A; Rossi L; Colato C; Zucchelli GC
    Clin Endocrinol (Oxf); 2007 Sep; 67(3):434-41. PubMed ID: 17555505
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study.
    Taïeb D; Sebag F; Cherenko M; Baumstarck-Barrau K; Fortanier C; Farman-Ara B; De Micco C; Vaillant J; Thomas S; Conte-Devolx B; Loundou A; Auquier P; Henry JF; Mundler O
    Clin Endocrinol (Oxf); 2009 Jul; 71(1):115-23. PubMed ID: 18803678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients.
    Schlumberger M; Hitzel A; Toubert ME; Corone C; Troalen F; Schlageter MH; Claustrat F; Koscielny S; Taieb D; Toubeau M; Bonichon F; Borson-Chazot F; Leenhardt L; Schvartz C; Dejax C; Brenot-Rossi I; Torlontano M; Tenenbaum F; Bardet S; Bussière F; Girard JJ; Morel O; Schneegans O; Schlienger JL; Prost A; So D; Archambeaud F; Ricard M; Benhamou E
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2487-95. PubMed ID: 17426102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic and therapeutic use of recombinant human TSH (rhTSH) in differentiated thyroid cancer.
    Pacini F; Castagna MG
    Best Pract Res Clin Endocrinol Metab; 2008 Dec; 22(6):1009-21. PubMed ID: 19041828
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma.
    Pacini F; Molinaro E; Lippi F; Castagna MG; Agate L; Ceccarelli C; Taddei D; Elisei R; Capezzone M; Pinchera A
    J Clin Endocrinol Metab; 2001 Dec; 86(12):5686-90. PubMed ID: 11739420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 85.